Ipamorelin

Ipamorelin is a pentapeptide (5 amino acids) that acts as a selective agonist of the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHS-R). By binding this receptor in the pituitary, it triggers the release of growth hormone in a pattern that mimics natural pulsatile secretion — a key advantage over exogenous HGH, which disrupts this natural rhythm. What distinguishes Ipamorelin from older GHRPs like GHRP-2 and GHRP-6 is its selectivity. It produces a clean GH pulse without meaningfully elevating cortisol or prolactin — hormones that are raised by less selective GHRPs and that can cause unwanted effects including fat gain, water retention, and reduced libido. This selectivity profile makes Ipamorelin the standard first-choice GHRP for most practitioners. Ipamorelin is available through some compounding pharmacies with a physician's prescription in the US, placing it in a more legitimate legal category than most research peptides, though its status varies by state and prescribing physician.

Growth hormone optimization is Ipamorelin's primary application. By stimulating pulsatile GH release, it elevates the 24-hour GH and IGF-1 profile without the flat-line suppression that comes from exogenous HGH. Over weeks and months of consistent use, this translates to gradual improvements in body composition — modest lean mass gains and progressive fat reduction, particularly in the abdominal region. Sleep quality improvement is one of the most consistently reported and earliest-experienced benefits. GH is predominantly released during deep sleep, and Ipamorelin's evening administration tends to amplify slow-wave sleep quality, which users typically notice within the first week of use. Recovery acceleration follows from the improved GH and IGF-1 environment. Connective tissue, muscle fiber repair, and training adaptation all benefit from an optimized GH axis, making Ipamorelin valuable for athletes even outside the context of body composition goals. Anti-aging applications are the primary driver of physician-prescribed Ipamorelin protocols. Declining GH and IGF-1 levels are a hallmark of biological aging; Ipamorelin offers a conservative, physiologically respectful way to restore more youthful GH pulsatility.

Ipamorelin's side effect profile is notably mild compared to other GHRPs. Because it does not stimulate cortisol or prolactin, the hunger spikes, fatigue, and water retention associated with GHRP-2 and GHRP-6 are largely absent. Transient water retention is the most commonly reported effect, typically noticeable in the first 2–4 weeks as the GH axis adapts. This generally resolves as the body acclimates to elevated GH levels. Headaches have been reported by some users, particularly early in a protocol or when increasing the dose. These are typically mild and transient. Long-term suppression of endogenous GH pulsatility is a theoretical concern with any exogenous GH secretagogue. Ipamorelin protocols typically include periodic cycling to mitigate this, though the suppression risk is lower than with continuous exogenous HGH use. Because Ipamorelin is frequently obtained without a prescription in the research chemical market, product quality variability is a real risk — degraded or contaminated peptide can cause local injection reactions.

Standard dose: 200–300 mcg per injection, administered 1–3 times daily. Most practitioners inject once at bedtime to align with natural GH release during sleep, or twice daily (morning and bedtime) for more aggressive GH optimization. CJC-1295 stack: When combined with CJC-1295 (the most common pairing), Ipamorelin dose typically stays at 200–300 mcg per injection while CJC-1295 is added at 100–200 mcg. The combination amplifies GH output synergistically because they act through complementary receptor pathways. Cycle length: Physician-prescribed protocols often run continuously with quarterly reassessment. Self-directed research use typically follows 12-week on / 4-week off cycles. Timing considerations: Inject on an empty stomach or at least 2 hours after a meal containing carbohydrates or fat, as insulin blunts GH release. Bedtime injection is the standard for sleep-quality optimization.

United States: Ipamorelin exists in a unique legal position. It is not FDA approved as a drug, but it can be legally prescribed and compounded by US compounding pharmacies as part of a physician's individualized patient treatment protocol. Many longevity clinics and TRT practices prescribe it routinely. Without a prescription, it is sold as a research chemical. WADA / Sports: Ipamorelin is prohibited by the World Anti-Doping Agency under the peptide hormones, growth factors category. Athletes in tested sports face the same consequences as with other prohibited peptides. European Union: Varies by member state. In most EU countries, Ipamorelin requires a prescription if obtained through licensed channels; gray market availability exists but legal exposure varies.

Ipamorelin + CJC-1295 (with DAC): The most popular GH optimization stack. Ipamorelin stimulates GH release via ghrelin receptors; CJC-1295 amplifies GH release via the GHRH receptor. The combination produces GH pulses significantly larger than either alone. Standard protocol: 200–300 mcg Ipamorelin + 100–200 mcg CJC-1295, injected together 1–2x daily. Ipamorelin + Sermorelin: A slightly gentler GH stack using two GHRH-pathway agents rather than the ghrelin + GHRH combination. Less potent than the CJC-1295 combination but with a very clean side effect profile. Ipamorelin + BPC-157: For athletes focused on recovery, adding BPC-157 to an Ipamorelin protocol addresses tissue repair at both the systemic (GH) and local (angiogenic) levels.

Ipamorelin — Common Questions